Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.40 |
| ▸ | ITGAV | P06756 | 5/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.40 |
| ▸ | RORC | P51449 | 4/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 2/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6421285 | 0.94 | ITGB3 (0.45) | ITGB3ITGAVITGA2BPPARDPPARA | |
| SCHEMBL6421900 | 0.94 | ITGB3 (0.45) | ITGB3ITGAVITGA2BPPARDPPARA | |
| SCHEMBL6419328 | 0.93 | ITGB3 (0.38) | ITGB3ITGAVITGA2BPDE4APDE4B | |
| SCHEMBL6419321 | 0.92 | ITGB3 (0.38) | ITGB3ITGAVITGA2BRORCOPRL1 | |
| SCHEMBL6419041 | 0.91 | ITGB3 (0.37) | ITGB3ITGAVITGA2B | |
| SCHEMBL6418120 | 0.91 | ITGB3 (0.43) | ITGB3ITGAVITGA2BRORCOPRL1 | |
| SCHEMBL6419279 | 0.88 | ITGB3 (0.45) | ITGB3ITGAVITGA2BPPARDPPARA | |
| SCHEMBL7398477 | 0.86 | ITGB3 (0.44) | ITGB3ITGAVITGA2BPPARDPPARA | |
| SCHEMBL6424968 | 0.86 | ITGB3 (0.45) | ITGB3ITGAVITGA2BPPARDPPARA | |
| SCHEMBL6418659 | 0.85 | ITGB3 (0.43) | ITGB3ITGAVITGA2BRORCPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825188-B2 | MORE POTENT INHIBITORS OF THE VITRONECTIN RECEPTOR THAN THE FIBRINOGEN | SMITHKLINE BEECHAM CORPORATION | 2004-11-30 | — | — | US | disclosed |
| US-20040082559-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082559-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | ITGB3 131/4885ITGAV 302/4885ITGA2B 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.